The global and national burden of chronic kidney disease attributable to ambient fine particulate matter air pollution: a modelling study

Benjamin Bowe,1,2 Elena Artimovich,1 Yan Xie,1,2 Yan Yan,1,3 Miao Cai,1,2 Ziyad Al-Aly1,4,5,6

ABSTRACT

Introduction We aimed to integrate all available epidemiological evidence to characterise an exposure–response model of ambient fine particulate matter (PM2.5) and the risk of chronic kidney disease (CKD) across the spectrum of PM2.5 concentrations experienced by humans. We then estimated the global and national burden of CKD attributable to PM2.5.

Methods We collected data from prior studies on the association of PM2.5 with CKD and used an integrative meta-regression approach to build non-linear exposure–response models of the risk of CKD associated with PM2.5 exposure. We then estimated the 2017 global and national incidence, prevalence, disability-adjusted life-years (DALYs) and deaths due to CKD attributable to PM2.5 in 194 countries and territories. Burden estimates were generated by linkage to risk estimates to Global Burden of Disease study datasets.

Results The exposure–response function exhibited evidence of an increase in risk with increasing PM2.5 concentrations, where the rate of risk increase gradually attenuated at higher PM2.5 concentrations. Globally, in 2017, there were 3 284 358.2 (95% UI 2 800 710.5 to 3 747 046.1) incident and 122 409 460.2 (108 142 312.2 to 136 424 137.9) prevalent cases of CKD attributable to PM2.5, and 6 593 134.6 (5 705 180.4 to 7 479 818.4) DALYs and 211 019.2 (184 292.5 to 236 520.4) deaths due to CKD attributable to PM2.5. The burden was disproportionately borne by low income and lower middle income countries and exhibited substantial geographic variability, even among countries with similar levels of sociodemographic development. Globally, 72.8% of prevalent cases of CKD attributable to PM2.5 and 74.2% of DALYs due to CKD attributable to PM2.5 were due to concentrations above 10 µg/m3, the WHO air quality guidelines.

Conclusion The global burden of CKD attributable to PM2.5 is substantial, varies by geography and is disproportionately borne by disadvantaged countries. Most of the burden is associated with PM2.5 levels above the WHO guidelines, suggesting that achieving those targets may yield reduction in CKD burden.

INTRODUCTION

A number of large epidemiological studies have described the relationship between ambient fine particulate matter of <2.5µm in aerodynamic diameter (PM2.5) and chronic kidney disease (CKD).1-3 Several experimental studies in mice and rats suggest that inhalation of PM2.5 promotes oxidative stress, inflammation and DNA damage in kidney tissue and leads to structural chronic kidney injury manifested by glomerulosclerosis, mesangial expansion, tubular atrophy and vascular damage, providing a plausible biological mechanism for the injurious effect of PM2.5 on the kidney.4-10 We recently described global and national estimates of CKD burden.

Key questions

What is already known?

► Ambient fine particulate matter (PM2.5) is associated with increased risk of chronic kidney disease (CKD).

What are the new findings?

► The shape of the relationship between PM2.5 and CKD suggests that increased PM2.5 concentrations were associated with increased risk of CKD at lower concentrations of PM2.5, and the rate of risk increase attenuated at higher levels of PM2.5.

► Globally, PM2.5 was associated with 3 284 358 incident cases of CKD each year.

► The burden of CKD attributable to PM2.5 was disproportionately borne by low income and lower middle income countries.

► Nearly 3/4 of the global burden of CKD attributable to PM2.5 was associated with PM2.5 levels above the WHO air quality guidelines.

What do the new findings imply?

► The global and national effort aimed at reducing burden of non-communicable diseases in general and kidney disease in particular should recognise fine particulate matter air pollution as a driver of burden of CKD globally.

► Achieving the WHO targets for fine particulate matter may yield substantial reduction in CKD burden.
attributable to PM$_{2.5}$ pollution based on an exposure–response function derived from a single US cohort with a narrow range of PM$_{2.5}$ exposure that may limit generalisability of these estimates. A significant knowledge gap exists in that the PM$_{2.5}$–CKD exposure–response function across the concentrations of PM$_{2.5}$ experienced by humans worldwide has not been characterised. Characterisation of an exposure–response function that integrates all available evidence will allow for more accurate estimation of CKD burden for a geographic area or a population group with well-defined exposure estimates. Estimation of burden of kidney disease will also contribute to the global discussion about the relationship between environmental air pollution and non-communicable diseases in general and specifically on the contribution of air pollution to the global and national burden of CKD.

In this work, we systematically searched all published reports on the relationship between PM$_{2.5}$ and CKD and used advanced methodologies to build and characterise an integrated non-linear exposure response model; we then generated estimates of the global and national burden of CKD attributable to PM$_{2.5}$ air pollution and estimated the burden attributable to levels of PM$_{2.5}$ exceeding the WHO PM$_{2.5}$ air quality standards.

METHODS

Characterisation of the risk of CKD associated with PM$_{2.5}$

To estimate the magnitude of the risk of CKD associated with PM$_{2.5}$ exposure across the spectrum of concentrations experienced by humans, we curated all available evidence for use in an integrative meta-regression approach. Prior work in the quantification of the global health risk of PM$_{2.5}$ has, for diseases with limited evidence across the entire PM$_{2.5}$ exposure range, additionally incorporated outcome associations with secondhand smoke, household air pollution and active smoking exposures as a means of calibration of exposure–response curve morphology at higher—otherwise understudied—PM$_{2.5}$ exposure values. However, recent literature has suggested that this approach may result in underestimation of risk, and therefore may not be the most optimal strategy to characterise risk if a preponderance of studies is available. Here, due to a potentially limited pool of PM$_{2.5}$ and CKD studies, we chose to estimate the non-linear exposure–response with methodological considerations based on both the integrated exposure–response (IER) method, which incorporates proxy exposures into estimation, and global exposure morality model (GEMM) method, which relies exclusively on PM$_{2.5}$ data, allowing for comparison of results generated from data with and without inclusion of proxy exposures.

Data curation

The protocol followed for identification of available evidence for incorporation in integrative meta-regression is reported following recommend guidelines (online supplementary material). We searched PubMed, Web of Science and the Cochrane library for literature on cohort, case–control and cross-sectional studies of the association between CKD and PM$_{2.5}$. Searches were also conducted to identify studies on CKD and secondhand smoke, household air pollution and active smoking. Following the strategies outlined in our protocol, searches on 20 May 2019 resulted in identifying for potential inclusion 322 studies on ambient fine particulate matter air pollution, 301 on secondhand smoke and 535 on active smoking. We screened these studies based on the following inclusion criteria: published in a peer-reviewed journal; reported as having a cohort, case–control or cross-sectional study design; provided a measure of relative risk; available in English; and assessed risk of a kidney disease outcome. We initially selected a CKD outcome definition of an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m$^2$, as this is the most commonly used outcome definition in epidemiological studies of CKD. However, this definition was relaxed for proxy exposures, due to paucity of usable studies, to include kidney disease outcomes that have displayed relative risks similar in magnitude to incident eGFR <60 mL/min/1.73 m$^2$ in prior literature, such as eGFR decline ≥30% from baseline or incident stage 4 CKD. We further excluded abstracts, as they lacked sufficient detail necessary for assessing risk of bias. Exposure type specific inclusion criteria included requiring studies on secondhand smoke to have a never-smoker comparison group and requiring studies on active smoking to have exposure definitions based on number cigarettes smoked per day. From selected studies, data were abstracted on study design, study outcome, range of exposure in the cohort, relative risk, relative risk uncertainty and aspects needed for risk of bias assessment. Studies risk of bias were scored using the Newcastle-Ottawa Scales for cohort and case–control studies and an adapted Newcastle-Ottawa scale for cross-sectional studies.

These scales allow for assignment of a numeric score to each study as a means of assessing the potential of bias, where a higher score indicates less potential. Each study was independently scored by two study team members; any discrepancies in score were resolved by additional scoring by third member, where the majority score was taken. Scoring components that were tailored specifically for this study have been included in the protocol (supplement). Studies that scored less than 50% of the maximum score were considered to lack suitability for inclusion in the analyses. After applying eligibility criteria, we identified for inclusion in analyses six studies on PM$_{2.5}$ and CKD, one study on secondhand smoke and CKD and three studies on active smoking and CKD. Further details are provided in the supplement.

Integrated non-linear exposure–response model

To incorporate all relevant evidence on the association between PM$_{2.5}$ and CKD, we constructed integrated non-linear exposure–response models by adapting aspects of the GEMM approach by Burnett et al (2018) and the

IER approach by Burnett et al (2014). The GEMM uses state-of-the-art modelling techniques to model the shape of the association between PM$_{2.5}$ and disease, leveraging study data that span the PM$_{2.5}$ exposure range experienced by humans. A series of random effects models that pool the relative risk among studies are constructed, each assuming a different monotonic functional form, which are then ensemble to create a final estimate of the exposure–response. The relative risk for a model may be equated by $RR_i(z) = \exp(\theta \log(1 + \frac{z - \tau}{\mu} \ast \omega(z)))$, where $RR_i(z)$ is the relative risk of $z$ the exposure value, $\theta$ is the parameter estimate and $\omega(z)$ is a logistic weighting function $\omega(z) = \frac{1}{1+\exp(-\frac{z-\mu}{\tau})}$ with $\tau$ the range of pollutant concentrations and $\alpha$, $\mu$ and $\tau$ predefined parameters that affect the shape and curvature of estimated relations. A study’s log($RR_i$) is then estimated as

$$
\log(\text{log}(\text{RR}_i)) = \theta \ast \left( \log(1 + \frac{z - \tau}{\mu}) \ast \left( 1+\exp\left(-\left(\frac{z-\mu}{\tau}\right)\right) \right) \right) - \left( \log(1 + \frac{z - \tau}{\mu}) \ast \left( 1+\exp\left(-\left(\frac{z-\mu}{\tau}\right)\right) \right) \right)
$$

where $z$ is the exposure for study $i$, $\tau$ is the $i$th exposure contrast, and hyperparameter values are set as $\alpha = (1.5, 3, 7.9)$, $\tau = (0.1, 0.2, 0.3, 0.4, 0.5, 0.6)$, and $\mu = (0th, 25th, 50th, 75th and 100th percentile of the PM$_{2.5}$ distribution among all study cohorts). This results in a total 150 curves with monotonic morphology that include linear, log-linear, supralinear, sublinear and S shapes, where the choice of hyperparameters were made in line with prior literature. These models were used to construct an ensemble estimate (a weighted average), where models are weighted by model fit (better fit resulting in a higher weight), and errors are obtained through bootstrap. In defining $z$ and $z_\tau$ for PM$_{2.5}$, if risk across several categories of exposure were given, the median of each category was used, otherwise the 5th and 95th percentile (assuming a normal distribution) were used. Contrast values for secondhand smoke and active smoking were based of prior literature, where moderate or severe passive smoking and number of cigarettes per day were translated into PM$_{2.5}$ mass inhaled concentration; if $z_\mu$ of zero was used. For the distribution of $\mu$, we assumed an uniform distribution between the minimal and maximal PM$_{2.5}$ values across the studies, as this allowed for a wide range of $\mu$ whose definition was not dominated by any one study with a large sample.

We employed four strategies in building the integrated non-linear exposure response model where we: (A) constructed the model using exclusively PM$_{2.5}$ study data and deweighted cross-sectional studies (this approach most closely emulates the analytic considerations and underlying assumptions of the GEMM model by Burnett et al); (B) constructed the model using PM$_{2.5}$ study data only and did not deweight cross-sectional studies; (c) additionally included data from the proxy exposure studies based on IER methods and deweighted cross-sectional studies; and (D) additionally included data from proxy exposure studies and did not deweight cross-sectional studies. Data were weighted by sampling variance and risk of bias using the quality effects weighting method as proposed by Doi and Thalib. Models in cross-sectional studies were deweighted by setting the risk of bias scores to a minimal value (1), a reflection of their inability to establish temporality in exposure–response relations (and the resultant higher risk of bias). Random effects models were fit using the rma.mv routine in R with the options: method="REML", optimizer="optim". A compound symmetry (CS) covariance structure was specified; for models that incorporated proxy exposures, a structure of ("CS", "CS"), adding correlation at the study (nested within exposure type) and exposure type levels, was used. Two studies that were done in potentially the same cohort by the same group were deweighted by being at the same study level. We additionally tested models specifying unstructured covariance; however, results were robust to this change, so the more parsimonious structure was kept. Resultant estimated risk are plotted for each of the four model versions, where a reference of 2.4 µg/m$^3$ is used, and all risk under 2.4 µg/m$^3$ was set to null, a reflection of burden estimation where a theoretical minimum risk exposure level (TMREL) of 2.4 µg/m$^3$ was used. As a means of visual presentation of fit for comparison of models with and without incorporation of proxy exposure data, we present for the best fit models (among the 150 models in the ensemble) a plot of the log($RR_i$) along with plots of the studies data points. One thousand replications using a parametric bootstrap approach was used in obtaining the UI, where the 2.5th and 97.5th percentiles of the resultant distribution of the ensemble estimates are reported.

**Burden estimation**

Data on the global burden of CKD were obtained from the 2017 Global Burden of Disease (GBD) study, where the GBD estimates CKD stage 1–5. Briefly, deaths due to CKD are estimated using vital registration and verbal autopsy data sources, to which a garbage coding algorithm is applied in order to redistribute cause of death codes deemed implausible or possibly miscoded. Prevalence is estimated from a collation of studies on population level CKD rates and is augmented by population-based surveys of renal function and renal registry reports, including end-stage renal disease data from 109 countries and data on CKD stage 3–5 from 59 countries. These data were linked with 2017 PM$_{2.5}$ global exposure estimates made available by GBD investigators; GBD estimates population weighted annual mean PM$_{2.5}$ concentrations for each country and territory at an approximate 11 km × 11 km resolution from a synthesis of satellite-based estimates, chemical transport models and ground-level measurements from 9960 monitors from 108 countries; the population-weighted root mean squared error of the model was 8.11 µg/m$^3$. Using risk estimates from the integrated
non-linear exposure–response models, we calculated the population attributable fraction (PAF) based on the equation \( PAF = 1 - \exp \left( \Delta v \left( z^T, z^{TMREL} \right) \right) \) where \( \Delta v \left( z^T, z^{TMREL} \right) \) is the difference in the transformed PM\(_{2.5}\) contrast between \( z^T \) and the population-weighted PM\(_{2.5}\) exposure estimate for the country or territory and \( z^{TMREL} \) the TMREL exposure level, and \( \beta \) the parameter estimate. We set a TMREL of 2.4 \( \mu g/m^3 \) and estimate the global CKD burden attributable to PM\(_{2.5}\). Further details are provided in the supplement. Ninety-five percent uncertainty intervals were obtained through 1000 realisations of the burden, where uncertainty was contributed to by risk estimation and uncertainty in GBD burden estimates. All reported numbers should be interpreted along with their 95% uncertainty intervals.

We then estimated the burden of CKD due to PM\(_{2.5}\) for 194 countries and territories based on the risk estimates of the integrated non-linear exposure–response model from the strategy of using only PM\(_{2.5}\) studies and deweighting the cross-sectional studies; we choose this strategy as our primary approach as it does not rely on proxy exposures (known to result in underestimation of risk), and—by deweighting cross-sectional studies—it will more closely approximate the ideal setting in which only high-quality longitudinal studies of PM\(_{2.5}\) and CKD are used. We estimated burden by World Bank income classification and conducted an expected to estimated ratio analyses by constructing a negative binomial model of the relation between age-standardised DALY rates of CKD due to PM\(_{2.5}\) and sociodemographic index (SDI), a summary measure of a country’s level of sociodemographic development, where SDI was treated as a restricted cubic spline to allow for non-linearity in the association. This ratio compares the estimated burden of CKD attributable to PM\(_{2.5}\) to the expected burden of CKD attributable to PM\(_{2.5}\) based on a country’s SDI. We furthermore estimated the burden of CKD attributable to PM\(_{2.5}\) concentrations above a TMREL (counterfactual) of 10 \( \mu g/m^3 \), the WHO air quality standard for average annual PM\(_{2.5}\) concentrations. Estimates for global burden and burden by World Bank income category were calculated through summation of the 194 countries and territories in our data. Maps were generated in ArcMap 10.5 (ESRI, Redlands, California, USA) and R Studio (R Core Team) and plots in SAS EG V.7.1 (SAS Institute, Cary, North Carolina, USA).

**Patient and public involvement**

No patients were involved in developing the hypothesis, the specific aims, or the research questions, nor were they involved in developing plans for design or implementation of the study. No patients were involved in the interpretation or writing up of results. There are no plans to disseminate the results of the research to study participants.

**RESULTS**

**An integrated non-linear exposure–response model**

We integrated all available evidence to build and characterise a non-linear exposure–response model of the relationship between PM\(_{2.5}\) and risk of CKD; a flow chart of data curation and description of included studies are available in supplementary figure S1 and table 1. For potential inclusion in the meta-regression analyses, we identified six studies on PM\(_{2.5}\), one study on second-hand smoke, and three studies on active smoking (online supplementary figure S1 and table 1), leading to a total of 30 data points, 15 of which were from PM\(_{2.5}\) studies. No studies on household air pollution and risk of CKD were identified.

We considered four analytic approaches to building the integrated non-linear exposure response function: (A) in analyses considering only studies on PM\(_{2.5}\) and risk of CKD and where cross-sectional studies were deweighted (we designated this as the primary model), the exposure–response function exhibited evidence of an increase in risk with increasing PM\(_{2.5}\) concentrations and the rate of risk increase gradually attenuated as PM\(_{2.5}\) concentration increased (figure 1A); (B) analyses considering only studies on PM\(_{2.5}\) and CKD and where cross-sectional studies were not deweighted produced consistent results (figure 1B); (C) analyses that also included active and passive smoking data as proxies of PM\(_{2.5}\) exposure and where cross-sectional studies were deweighted yielded an exposure–response function that exhibited less risk for each given PM\(_{2.5}\) concentration than when proxy exposures were not included (figure 1C); (D) analyses that also included active and passive smoking data as proxies of PM\(_{2.5}\) exposure and where cross-sectional studies were not deweighted yielded results consistent with those in approach C (figure 1D). Plots of estimated risk versus study data points suggested that compared with models built using only PM\(_{2.5}\) data, incorporation of proxy exposures resulted in underestimation of risk associated with PM\(_{2.5}\) exposure (online supplementary figures S2A–D).

**Global Burden of CKD attributable to PM\(_{2.5}\) air pollution**

We estimated the global burden of CKD attributable to air pollution using the PM\(_{2.5}\) exposure–risk function where only studies on PM\(_{2.5}\) and CKD were used and cross-sectional studies were deweighted (we designated this as the primary model and is depicted in figure 1A). At the global level, our estimates suggest that incidence of CKD attributable to PM\(_{2.5}\) air pollution was 3 284 358.2 (95% UI 2 800 710.5 to 3 747 046.1) and prevalence was 122 409 460.2 (108 142 312.2 to 136 424 137.9). There were 6 593 134.6 (5 705 180.4 to 7 436 870.1) DALYs and 211 019.2 (184 292.5 to 236 520.4) deaths due to CKD attributable to PM\(_{2.5}\) pollution. Rates per 100 000 and age-standardised rates per 100 000 for incidence, prevalence,
Table 1  Summary of studies incorporated in integrated non-linear exposure-response modelling

<table>
<thead>
<tr>
<th>Reference year</th>
<th>Design</th>
<th>Sample size</th>
<th>Exposure source</th>
<th>Mean or median exposure range (SD or IQR)</th>
<th>CKD definition</th>
<th>Adjustments</th>
<th>Exposure contrast</th>
<th>RR (95% CI)</th>
<th>Risk of bias score</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2018)</td>
<td>Cohort</td>
<td>2482737</td>
<td>PM$_{2.5}$</td>
<td>11.8 (5.0–22.1) eGFR &lt;60mL/min/1.73m²</td>
<td>Age, race, sex, cancer, cardiovascular disease, chronic lung disease, diabetes mellitus, hyperlipidaemia, hypertension, baseline eGFR, BMI, smoking status, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, county population density, number of outpatient eGFR measurements, number of hospitalisations and county percent in poverty.</td>
<td>Quartile 2 versus 1</td>
<td>1.02 (0.97 to 1.07)</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>(2018)</td>
<td>Cohort</td>
<td>100829</td>
<td>PM$_{2.5}$</td>
<td>27.1 (5.8–49.6) eGFR &lt;60mL/min/1.73m²</td>
<td>Age, sex, educational level, smoking status, alcohol consumption, BMI, systolic BP, fasting glucose, total cholesterol, self-reported heart disease or stroke and baseline eGFR.</td>
<td>Quartile 2 versus 1</td>
<td>1.05 (0.95 to 1.15)</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>(2018)</td>
<td>Cross-sectional</td>
<td>21656</td>
<td>PM$_{2.5}$</td>
<td>26.6 (5.0) eGFR &lt;60mL/min/1.73m²</td>
<td>Age, sex, fasting glucose, cholesterol, hypertension, BMI, distance to major road, smoking status, alcohol consumption and education level.</td>
<td>Every 5.67µg/m³ increase</td>
<td>1.03 (0.97 to 1.09)</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>(2018)</td>
<td>Cross-sectional</td>
<td>8497</td>
<td>PM$_{2.5}$</td>
<td>24.3 (12.8–48.2) eGFR &lt;60mL/min/1.73m²</td>
<td>Age, sex, BMI, education level, smoking status, alcohol consumption, hypertension and diabetes.</td>
<td>Every 4.1µg/m³ increase</td>
<td>1.01 (0.96 to 1.06)</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>(2018)</td>
<td>Cross-sectional</td>
<td>1164057</td>
<td>PM$_{2.5}$</td>
<td>12.2 (6.1–16.8) eGFR &lt;60mL/min/1.73m²</td>
<td>Age, sex, race/ethnicity, hypertension, diabetes and urban/rural status.</td>
<td>Quartile 2 versus 1</td>
<td>1.02 (0.99 to 1.04)</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>(2018)</td>
<td>Cross-sectional</td>
<td>5090</td>
<td>PM$_{2.5}$</td>
<td>12.2 (0.6) eGFR &lt;60mL/min/1.73m²</td>
<td>Age, sex, BMI, education level, neighbourhood socioeconomic status, medical insurance, smoking status, physical activity, alcohol consumption, occupation, hyperlipidaemia, use of non-steroidal anti-inflammatory drugs, diuretic medication, statin medications, diabetes and hypertension and accounting for clustering by census tract.</td>
<td>Every 1µg/m³ increase</td>
<td>1.00 (0.82 to 1.22)</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>(2018)</td>
<td>Cohort</td>
<td>1498</td>
<td>Passive smoking</td>
<td>–</td>
<td>eGFR &lt;60mL/min/1.73m²</td>
<td>Age, sex, BMI, systolic BP, history of hypertension, history of diabetes, alcohol status, education levels, income levels, marital status, haemoglobin and serum albumin.</td>
<td>Moderate secondhand smoke</td>
<td>1.58 (0.94 to 2.66)</td>
<td>9</td>
</tr>
<tr>
<td>(2018)</td>
<td>Case-Control</td>
<td>1224</td>
<td>Active smoking</td>
<td>–</td>
<td>eGFR &lt;60mL/min/1.73m²</td>
<td>Age, gender, education level, alcohol consumption, use of paracetamol and salicylates, pipe smoking, cigar smoking and snuff use.</td>
<td>1–10 cigarettes per day versus no smoking</td>
<td>0.89 (0.66 to 2.11)</td>
<td>7</td>
</tr>
<tr>
<td>(2018)</td>
<td>Cohort</td>
<td>3648</td>
<td>Active smoking</td>
<td>–</td>
<td>eGFR decline ≥ 30%</td>
<td>Age, sex, BMI, diabetes, hypertension, total cholesterol, education level, physical activity, prevalent cardiovascular disease and alcohol consumption.</td>
<td>1–19 cigarettes per day versus no smoking</td>
<td>1.75 (1.18 to 2.59)</td>
<td>6</td>
</tr>
</tbody>
</table>

Continued
### Table 1 Continued

<table>
<thead>
<tr>
<th>Reference (year)</th>
<th>Design</th>
<th>Sample size</th>
<th>Exposure source</th>
<th>Mean or median exposure range (SD or IQR)</th>
<th>CKD definition</th>
<th>Adjustments</th>
<th>Exposure contrast</th>
<th>RR (95% CI)</th>
<th>Risk of bias score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hippisley-Cox and Coupland (2010)*</td>
<td>Cohort</td>
<td>3156494</td>
<td>Active smoking</td>
<td>eGFR &lt;45 mL/min/1.73 m²</td>
<td>Age, ethnicity, deprivation, smoking, BMI, systolic BP, diabetes, rheumatoid arthritis, cardiovascular disease, treated hypertension, congestive cardiac failure, peripheral vascular disease, use of non-steroidal anti-inflammatory drugs and family history of kidney disease, systemic lupus erythematosus and kidney stones were additional adjusted for models in women.</td>
<td>&lt;10 cigarettes/day versus no smoking in men</td>
<td>1.30 (1.15 to 1.23)</td>
<td>10-19 cigarettes/day versus no smoking in men</td>
<td>1.27 (1.21 to 1.34)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt;19 cigarettes/day versus no smoking in women</td>
<td>1.43 (1.34 to 1.52)</td>
<td>10-19 cigarettes/day versus no smoking in men</td>
<td>1.24 (1.16 to 1.32)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;10 cigarettes/day versus no smoking in men</td>
<td>1.15 (1.08 to 1.22)</td>
<td>10-19 cigarettes/day versus no smoking in men</td>
<td>1.25 (1.16 to 1.34)</td>
</tr>
</tbody>
</table>

*Incorporated in models when proxy exposures were included.

BML, body mass index; BP, blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; PM₂.₅, ambient fine particulate matter.

---

**Burden of CKD and sociodemographic development**

We estimated the burden of CKD attributable to PM₂.₅ levels above the WHO limit of 10 μg/m³. We then estimated the burden of CKD attributable to PM₂.₅ concentrations above the WHO air quality standards for PM₂.₅ (10 μg/m³). Our results suggest that 27.8% of prevalent cases of CKD attributable to PM₂.₅ were due to concentrations above 10 μg/m³ (table 4). Overall, there was substantial variation in age-standardised incidence, prevalence, and death rates due to CKD attributable to PM₂.₅ across geographical regions and demographic groups.

---

**Burden of DALYs and death due to CKD attributable to PM₂.₅ air pollution in 194 countries and territories**

We estimated the burden of DALYs and death due to CKD attributable to PM₂.₅ air pollution in 194 countries and territories using a model that incorporated smoking data. Our results suggest that 72.8% of prevalent cases of CKD attributable to PM₂.₅ and 74.2% of DALYs due to CKD attributable to PM₂.₅ were due to concentrations above 10 μg/m³ (table 4). A map of the prevalent number of cases of CKD attributable to PM₂.₅ and population attributable fraction (PAF) for each country is presented in figure 2A. The overall burden of CKD attributable to PM₂.₅ is presented in figure 2B. The age-standardised DALYs rates, PAF, and age-standardised DALYs rates attributable to PM₂.₅ are presented in online supplementary tables S1 and S5.
DISCUSSION

In this work, we integrated all available evidence of the relationship between \( \text{PM}_{2.5} \) and risk of CKD to build and characterise a non-linear exposure–response function to describe the risk of CKD across \( \text{PM}_{2.5} \) concentrations experienced by humans. We estimated that in 2017, there were 3,284,358.2 (95% UI 2,800,710.5 to 3,747,046.1) incident and 122,409,460.2 (108,142,312.2 to 136,424,137.9) prevalent cases of CKD attributable to \( \text{PM}_{2.5} \); and 6,593,134.6 (5,705,180.4 to 7,479,818.4) DALYs and 211,019.2 (184,292.5 to 236,520.4) deaths due to CKD attributable to \( \text{PM}_{2.5} \) pollution. We produced estimates of CKD burden attributable to \( \text{PM}_{2.5} \) pollution for 194 countries and territories and provided evidence that the burden is disproportionately borne by low income and lower middle income countries. Finally, we also show that 72.8% of the prevalent cases of CKD attributable to \( \text{PM}_{2.5} \) air pollution and 74.2% of DALYs due to CKD attributable to \( \text{PM}_{2.5} \) were associated with \( \text{PM}_{2.5} \) levels above the WHO air quality standards.

We employed four strategies to build the non-linear exposure-risk function. We observed that deweighting cross-sectional studies did not appreciably influence the morphology of the risk–exposure model, nor did it result in substantially different estimates. However, the inclusion of active and passive smoking as proxies of \( \text{PM}_{2.5} \) exposure resulted in a much smaller risk estimates and subsequently much lower burden estimates. These results are consistent with findings from Burnett and collaborators, who noted that prior methodological approaches that incorporated active and passive smoke as proxy exposures of \( \text{PM}_{2.5} \) resulted in significant underestimation of burden of death attributable to \( \text{PM}_{2.5} \) pollution. More accurate estimation of CKD burden hinges on the availability of high-quality cohort studies representing the full spectrum of \( \text{PM}_{2.5} \) exposure experienced by humans.

The WHO now officially recognises air pollution as a risk factor for non-communicable diseases, and there is increasing recognition that tackling air pollution is critical to addressing the rising tide of non-communicable diseases. Estimates of burden of non-communicable diseases attributable to air pollution are important to inform this effort, guide policy and inform future directions. In particular, as experimental evidence has accumulated over the past decade providing plausible biological mechanism to explain the effect of \( \text{PM}_{2.5} \) on the kidney, and as large epidemiological studies linking \( \text{PM}_{2.5} \) exposure with risk of kidney disease and death due to kidney disease became available, the need...
for a greater understanding and more accurate estimation of the burden of kidney disease attributable to PM$_{2.5}$ air pollution became more evident.$^{16,58}$ We previously provided estimates of CKD burden attributable to PM$_{2.5}$, which relied on a single large US cohort study.$^{11}$ In this work, we integrated all available evidence and provided global and national estimates of burden of CKD attributable to PM$_{2.5}$ air pollution. The GBD study framework also facilitates comparative evaluation of the health sequelae of PM$_{2.5}$ across geographies and over time.

We observed that estimates of the burden of CKD attributable to PM$_{2.5}$ air pollution exhibited substantial geographic variability and were higher in low and lower middle income countries—countries that are least equipped to deal with the untoward health consequences of pollution.$^{11,35,60-62}$ Variations in PM$_{2.5}$-associated CKD burden reflect the influence of differences in PM$_{2.5}$ exposure and differences in underlying CKD rates. Our estimated to expected ratio analyses based on SDI suggest that at both ends of the development spectrum there are several countries that exhibited much higher (and much lower) burden than expected. To the extent that sociodemographic and economic development may be both a driver for environmental air pollution and enabler of mitigation mechanisms, the bidirectional diversion from expected burden across the SDI spectrum suggests the likely presence of other forces (or drivers) of this burden and the potential—for so far unrealised—opportunities for reduction in burden.$^{35,60}$

<table>
<thead>
<tr>
<th>Modelling strategy</th>
<th>Proxy exposures included</th>
<th>PAF (95% UI)</th>
<th>Measure</th>
<th>Incidence (95% UI)</th>
<th>Prevalence (95% UI)</th>
<th>DALY (95% UI)</th>
<th>Death (95% UI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CS studies</strong></td>
<td><strong>w/ deweighted</strong></td>
<td><strong>Yes</strong></td>
<td><strong>No</strong></td>
<td><strong>Number</strong></td>
<td><strong>Rate (per 100 000)</strong></td>
<td><strong>Age-standardised rate (per 100 000)</strong></td>
<td><strong>Yes</strong></td>
</tr>
<tr>
<td></td>
<td><strong>w/ deweighted</strong></td>
<td><strong>Yes</strong></td>
<td><strong>No</strong></td>
<td><strong>Number</strong></td>
<td><strong>Rate (per 100 000)</strong></td>
<td><strong>Age-standardised rate (per 100 000)</strong></td>
<td><strong>Yes</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>19.5 (18.0 to 21.0)</td>
<td>3.284 358.2 (2.800 710.5 to 3.747 046.1)</td>
<td>122 409 460.2 (108 142 312.2 to 136 424 159.7)</td>
<td>5 693 134.6 (5 075 180.4 to 7 436 870.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4.5 (3.7 to 5.0)</td>
<td>44.5</td>
<td>1670.3 (1475.9 to 1861.4)</td>
<td>89.9 (77.8 to 101.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>9.7 (4.2 to 5.6)</td>
<td>49.7</td>
<td>1789.6 (1585.0 to 1989.2)</td>
<td>101.6 (87.6 to 115.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17.4 (15.7 to 19.1)</td>
<td>2 908 401.2 (2 482 793.5 to 3 378 084.4)</td>
<td>108 679 458.9 (94 881 702.0 to 123 149 917.2)</td>
<td>5 673 622.6 (5 084 600.9 to 6 754 641.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>39.4 (33.7 to 45.8)</td>
<td>1484.6 (1296.6 to 1682.2)</td>
<td>80.1 (69.4 to 92.1)</td>
<td>2.5 (2.2 to 2.9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>44.3 (38.0 to 51.2)</td>
<td>1597.3 (1399.1 to 1806.3)</td>
<td>90.8 (78.2 to 104.7)</td>
<td>3.4 (2.9 to 3.9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.6 (5.1 to 8.2)</td>
<td>1 089 779.3 (800 761.9 to 1 402 860.4)</td>
<td>41 023 348.8 (30 636 668.8 to 52 184 444.4)</td>
<td>2 223 125.6 (1 652 353.6 to 2 838 639.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>14.8 (10.9 to 19.1)</td>
<td>561.6 (420.2 to 713.6)</td>
<td>30.4 (22.6 to 38.8)</td>
<td>1.0 (0.7 to 1.2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>16.8 (12.5 to 21.5)</td>
<td>607.9 (457.6 to 767.8)</td>
<td>34.6 (25.8 to 44.0)</td>
<td>1.3 (1.0 to 1.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.2 (4.7 to 7.8)</td>
<td>1 024 163.8 (744 761.8 to 1 325 643.8)</td>
<td>38 602 132.4 (28 647 072.0 to 49 027 426.1)</td>
<td>2 083 387.4 (1 545 110.3 to 2 673 053.9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>13.9 (10.1 to 18.0)</td>
<td>528.7 (393.1 to 671.3)</td>
<td>26.6 (21.2 to 36.5)</td>
<td>0.9 (0.7 to 1.2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>15.9 (11.7 to 20.4)</td>
<td>573.0 (429.2 to 725.6)</td>
<td>32.6 (24.1 to 41.7)</td>
<td>1.2 (0.9 to 1.5)</td>
</tr>
</tbody>
</table>

Rates are per 100 000 persons.

CKD, chronic kidney disease; CS, cross-sectional; DALY, disability-adjusted life-year; PAF, population attributable fraction; PM$_{2.5}$, ambient fine particulate matter; UI, uncertainty interval.

Table 2: Estimates of the global burden of CKD attributable to PM$_{2.5}$ air pollution

Figure 2  Global burden of CKD attributable to PM$_{2.5}$ in 194 countries and territories. (A) Prevalence of CKD attributable to PM$_{2.5}$; (B) age-standardised disability-adjusted life-years (DALYs) rate (per 100 000) due to CKD attributable to PM$_{2.5}$. Countries are coloured by decile. CKD, chronic kidney disease; PM$_{2.5}$, ambient fine particulate matter. ATG, Antigua and Barbuda; FSM, Federated States of Micronesia; Isl, Island; LCA, Saint Lucia; TLS, Timor-Leste; TTO, Trinidad and Tobago; VCT, Saint Vincent and the Grenadines.
Table 3  Estimates of the population attributable fraction and age-standardised burden rate (per 100 000) of CKD attributable to PM$_{2.5}$ by World Bank income classification

<table>
<thead>
<tr>
<th>World Bank income classification</th>
<th>PAF (95% UI)</th>
<th>Incidence (95% UI)</th>
<th>Prevalence (95% UI)</th>
<th>DALY (95% UI)</th>
<th>Death (95% UI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low income</td>
<td>19.2 (17.6 to 20.8)</td>
<td>66.0 (56.8 to 74.8)</td>
<td>1925.2 (1699.1 to 2147.7)</td>
<td>127.0 (103.5 to 148.8)</td>
<td>4.8 (3.9 to 5.7)</td>
</tr>
<tr>
<td>Lower middle income</td>
<td>23.7 (22.0 to 25.5)</td>
<td>68.2 (58.8 to 77.3)</td>
<td>2350.2 (2087.8 to 2605.3)</td>
<td>149.1 (128.8 to 168.7)</td>
<td>5.4 (4.6 to 6.1)</td>
</tr>
<tr>
<td>Upper middle income</td>
<td>18.3 (16.8 to 19.8)</td>
<td>34.0 (28.9 to 38.8)</td>
<td>1498.7 (1324.2 to 1668.9)</td>
<td>66.2 (58.4 to 73.9)</td>
<td>2.5 (2.2 to 2.8)</td>
</tr>
<tr>
<td>High income</td>
<td>8.9 (8.0 to 9.7)</td>
<td>21.0 (17.6 to 24.1)</td>
<td>643.1 (561.8 to 722.0)</td>
<td>25.6 (21.3 to 29.7)</td>
<td>1.1 (0.9 to 1.3)</td>
</tr>
</tbody>
</table>

Estimates were generated using the integrated non-linear exposure response model using only PM$_{2.5}$ data where cross-sectional studies were deweighted.

CKD, chronic kidney disease; DALY, disability-adjusted life-year; PAF, population attributable fraction; PM$_{2.5}$, ambient fine particulate matter; UI, uncertainty interval.

Our estimates suggest that the majority of the burden was attributable to PM$_{2.5}$ levels above the WHO air quality guidelines for annual mean PM$_{2.5}$ concentrations. The findings emphasise that for much of the world PM$_{2.5}$ levels remain too high and that further effort to reduce PM$_{2.5}$ concentrations—and meet the WHO air quality standards—may be associated with substantial reduction in burden of CKD worldwide.\textsuperscript{11, 16}

This study has several limitations. While we integrated data from all available studies on PM$_{2.5}$ and CKD, our approach is inherently limited by the availability of data, and in particular, the paucity of large high-quality longitudinal studies of PM$_{2.5}$ and CKD from areas with very high PM$_{2.5}$ concentrations\textsuperscript{3} and the lack of data for very low levels of PM$_{2.5}$ below the TMREL. There was also limited geographic diversity in the studies of PM$_{2.5}$ and CKD in that most were from western countries, few from East Asia, and none from Africa and the southern hemisphere. Our analyses did not consider potential heterogeneity of effect by population or regional characteristics, and we did not account for potential temporal or geospatial differences in composition and toxic content of PM$_{2.5}$. PM$_{2.5}$ is also associated with diabetes and hypertension, both known causal drivers of CKD; while the studies included in our metaregression analyses considered hypertension and diabetes as potential confounders, addressing the knowledge gap of whether to what extent the association between PM$_{2.5}$ and CKD is mediated by diabetes and hypertension may help further refine PM$_{2.5}$ burden attribution. Causal interpretation should be made with caution. In this work, we estimated the global and national burden of CKD attributable to PM$_{2.5}$ using GBD data for CKD burden, and PM$_{2.5}$ exposure estimates at the national level.\textsuperscript{63} Our analyses do not include potential exposure to air pollutants other than PM$_{2.5}$ or to indoor air pollutants and do not provide further insight into PM$_{2.5}$ attributable burden at the subnational level. Our estimates of CKD attributable to PM$_{2.5}$ at the global and national levels reflect the influence of PM$_{2.5}$ levels across the globe and of demography and underlying CKD rates.

Strengths include the application of state-of-the-art methodologies to build an integrated exposure response function using data from several high-quality longitudinal cohort studies of PM$_{2.5}$ and CKD, and in particular, the incorporation of studies from China where PM$_{2.5}$ exposure is much higher than western countries. The functional form of our integrated exposure–response function and the resulting estimates of burden were not

Figure 3  Map of the estimated to expected ratio of age-standardised disability-adjusted life-years (DALYs) due to CKD attributable to PM$_{2.5}$ based on level of sociodemographic development. Countries and territories are coloured by the estimated to expected ratio the age-standardised DALYs rate based on their sociodemographic index (SDI), where a ratio greater than one indicates greater than expected age-standardised DALYs, while a ratio less than one is less than expected. CKD, chronic kidney disease.
sensitive to deweighting of cross-sectional studies. To build our estimates, we leveraged the availability of the 2017 GBD data, which is the most comprehensive compilation and analysis of global health information available, and provided several measures of burden including incidence, prevalence, DALYs and death.

In sum, we built and characterised an integrated non-linear exposure–response model for PM$_{2.5}$ and CKD and show that the global burden of CKD attributable to PM$_{2.5}$ air pollution is substantial. The estimated burden was unevenly distributed, and more disproportionately borne by low income and lower middle income countries. That nearly 3/4 of the burden is associated with PM$_{2.5}$ concentrations above the WHO air quality standards suggests potential unrealised opportunities for reduction in CKD burden.

**Table 4** Estimates of the global burden of CKD due to PM$_{2.5}$ above the WHO air quality guidelines for PM$_{2.5}$ (10 µg/m$^3$)

<table>
<thead>
<tr>
<th>Measure</th>
<th>PAF (95% UI)</th>
<th>Incidence (95% UI)</th>
<th>Prevalence (95% UI)</th>
<th>DALY (95% UI)</th>
<th>Death (95% UI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>14.7 (13.6 to 15.8)</td>
<td>2 338 578.5 (2 022 602.3 to 2 673 492.1)</td>
<td>89 111 428.8 (79 647 475.3 to 99 404 342.0)</td>
<td>4 894 988.1 (4 292 865.7 to 5 536 504.6)</td>
<td>152 388.2 (134 514.1 to 171 678.7)</td>
</tr>
<tr>
<td>Rate (per 100 000)</td>
<td>32.2 (27.8 to 36.8)</td>
<td>1230.3 (1099.6 to 1372.4)</td>
<td>67.4 (59.2 to 76.3)</td>
<td>2.1 (1.9 to 2.4)</td>
<td></td>
</tr>
<tr>
<td>Age-standardised rate (per 100 000)</td>
<td>37.3 (32.5 to 42.5)</td>
<td>1351.6 (1210.7 to 1504.9)</td>
<td>77.5 (67.8 to 87.9)</td>
<td>2.9 (2.5 to 3.3)</td>
<td></td>
</tr>
</tbody>
</table>

Estimates were generated using the integrated non-linear exposure response model using only PM$_{2.5}$ data where cross-sectional studies were deweighted.

**Map disclaimer** The depiction of boundaries on the map(s) in this article do not imply the expression of any opinion whatsoever on the part of BMJ (or any member of its group) concerning the legal status of any country, territory, jurisdiction or area or of its authorities. The map(s) are provided without any warranty of any kind, either express or implied.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not required.

**Ethics approval** This research project was reviewed and approved by the Institutional Review Board of the VA Saint Louis Health Care System.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** All data is publically available. Data are available upon request.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iD**

Ziyad Al-Aly http://orcid.org/0000-0002-2600-0434

**REFERENCES**


